AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for 26S proteasome regulatory subunit 4

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our high-tech, dedicated method is applied to construct targeted libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

P62191

UPID:

PRS4_HUMAN

Alternative names:

26S proteasome AAA-ATPase subunit RPT2; Proteasome 26S subunit ATPase 1

Alternative UPACC:

P62191; B4DR63; P49014; Q03527; Q6IAW0; Q6NW36; Q96AZ3

Background:

The 26S proteasome regulatory subunit 4, also known as PSMC1, plays a crucial role in cellular homeostasis. It is a component of the 26S proteasome, a complex essential for the ATP-dependent degradation of ubiquitinated proteins. This process is vital for removing misfolded or damaged proteins and those no longer needed, thereby participating in cell cycle progression, apoptosis, and DNA damage repair.

Therapeutic significance:

The association of PSMC1 with the neurodevelopmental disorder characterized by poor growth, spastic tetraplegia, and hearing loss highlights its potential as a therapeutic target. Understanding the role of PSMC1 could open doors to potential therapeutic strategies for this and related disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.